

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



上海復旦張江生物醫藥股份有限公司
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.*

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code:1349)

CLARIFICATION ANNOUNCEMENT

Reference is made to the announcement of 上海復旦張江生物醫藥股份有限公司 (Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.) (the “**Company**”) dated 11 August 2015 (the “**Announcement**”) in relation to the interim results of the Company and its subsidiaries (the “**Group**”) for the six months ended 30 June 2015. Terms used herein shall have the same meanings as those defined in the Announcement unless the context requires otherwise.

The Board would like to clarify that: 1) the title of the Announcement on the Chinese version of website of the Stock Exchange of Hong Kong Limited is: 截至二零一五年六月三十日止六個月中期業績公告; and 2) the main reason for the increase in the Group’s revenue for the six months ended 30 June 2015 is that sales of Libod (里葆多[®], 鹽酸多柔比星脂質體, Doxorubicin liposome) and ALA (艾拉[®], 鹽酸氨酮戊酸散), the major products of the Group, have contributed significant revenue to the Group during the period and their sales volume increased about 54% and 26%, respectively, from that of the corresponding period last year.

Save as disclosed herein, the contents of the Announcement remain unchanged.

By Order of the Board
Wang Hai Bo
Chairman

As at the date on the publication of this announcement, the Board comprises:

Mr. Wang Hai Bo (Executive Director)

Mr. Su Yong (Executive Director)

Mr. Zhao Da Jun (Executive Director)

Ms. Ke Ying (Non-executive Director)

Mr. Shen Bo (Non-executive Director)

Ms. Yu Xiao Yang (Non-executive Director)

Mr. Zhou Zhong Hui (Independent Non-executive Director)

Mr. Lam Yiu Kin (Independent Non-executive Director)

Mr. Xu Qing (Independent Non-executive Director)

Shanghai, the PRC

12 August 2015

** For identification purpose only*